Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...
1d
Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...
FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...
The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...
Journavx, a non-opioid treatment for moderate to severe acute pain, received FDA approval with a broad label. The drug’s pricing strategy, set at a daily maintenance price of $31, has exceeded ...
Journavx, a non-opioid treatment for moderate to severe acute pain, received FDA approval with a broad label. The drug’s pricing strategy, set at a daily maintenance price of $31, has exceeded ...
Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...
The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...
Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback